FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379339735> ?p ?o ?g. }

• W4379339735 endingPage "e20002" @default.
• W4379339735 startingPage "e20002" @default.
• W4379339735 abstract "e20002 Background: While BCMA-targeted CAR T therapies have yielded unprecedented efficacy in patients with multiple myeloma, most patients (pts) experience disease relapse. Treatment after progression on CAR T has become an unmet need given the limited novel treatment options available. We evaluated clinical outcomes for pts relapsing after BCMA CAR T. Methods: This was a single-center retrospective analysis including pts who had been treated with a BCMA-targeted CAR T therapy prior to 12/31/22 and then had disease progression. Data for all subsequent lines of therapy were collected, and best response to therapy was graded as per IMWG criteria. Statistics were descriptive in nature. Results: Thirty pts treated with BCMA CAR T (14 trial, 16 commercial) relapsed. The cohort of median age 61 had notable disease characteristics of 40% with high-risk FISH and 30% with extramedullary disease (EMD). The median number of prior lines of therapy (LOT) was 5, with 80% triple-class refractory and 47% penta-refractory. Patients treated with late BCMA CAR T (≥ 4 prior LOT; n=20) had higher rates of EMD (40% v 10%), triple-class refractory (90% v 60%), and penta-refractory disease (55% v 30%) compared to pts who received early CAR T (< 4 prior LOT; n=10). At data cutoff, 4 pts died without receiving subsequent therapy and 1 pt was pending start of their first regimen. The remaining 25 pts received 58 salvage therapies, of which 54 regimens were evaluable for response. The overall response rate (ORR) for all regimens was 46%. Median overall survival (OS) was not reached, and the 6 and 12-month OS rates were 83% and 77% respectively. ORR and median progression free survival (PFS) stratified by the specific type of salvage therapy are shown in the table. Patients who received a regimen consisting only of agents they had received in a prior LOT had an ORR of 57% and median PFS of 3.6 months. Patients who received early CAR T had a higher ORR to all subsequent salvage therapies (59% v 33%), longer median PFS (4.6 months v 1.6 months), and higher 12-month OS (90% v 70%). Conclusions: For pts with progression after BCMA CAR T, treatment with another BCMA CAR T or transplant had more favorable outcomes. Retreatment with prior therapies resulted in disease control for a fair number of patients, which can serve as a bridge to another novel therapy. The pts treated with early CAR T had more favorable post-progression outcomes than late CAR T, yet 70% of pts who received late CAR T were alive at 1 year post-progression. [Table: see text]" @default.
• W4379339735 created "2023-06-05" @default.
• W4379339735 creator A5042510751 @default.
• W4379339735 creator A5060313982 @default.
• W4379339735 creator A5071516639 @default.
• W4379339735 creator A5074144760 @default.
• W4379339735 creator A5080882830 @default.
• W4379339735 creator A5092085123 @default.
• W4379339735 date "2023-06-01" @default.
• W4379339735 modified "2023-09-25" @default.
• W4379339735 title "Clinical outcomes of patients with multiple myeloma following disease progression after BCMA-targeted CAR T-cell therapy." @default.
• W4379339735 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e20002" @default.
• W4379339735 hasPublicationYear "2023" @default.
• W4379339735 type Work @default.
• W4379339735 citedByCount "0" @default.
• W4379339735 crossrefType "journal-article" @default.
• W4379339735 hasAuthorship W4379339735A5042510751 @default.
• W4379339735 hasAuthorship W4379339735A5060313982 @default.
• W4379339735 hasAuthorship W4379339735A5071516639 @default.
• W4379339735 hasAuthorship W4379339735A5074144760 @default.
• W4379339735 hasAuthorship W4379339735A5080882830 @default.
• W4379339735 hasAuthorship W4379339735A5092085123 @default.
• W4379339735 hasConcept C121332964 @default.
• W4379339735 hasConcept C121608353 @default.
• W4379339735 hasConcept C126322002 @default.
• W4379339735 hasConcept C141071460 @default.
• W4379339735 hasConcept C142424586 @default.
• W4379339735 hasConcept C143998085 @default.
• W4379339735 hasConcept C2776364478 @default.
• W4379339735 hasConcept C2776694085 @default.
• W4379339735 hasConcept C2777701055 @default.
• W4379339735 hasConcept C2780775027 @default.
• W4379339735 hasConcept C2781413609 @default.
• W4379339735 hasConcept C2911194787 @default.
• W4379339735 hasConcept C3875195 @default.
• W4379339735 hasConcept C71924100 @default.
• W4379339735 hasConcept C72563966 @default.
• W4379339735 hasConcept C87355193 @default.
• W4379339735 hasConceptScore W4379339735C121332964 @default.
• W4379339735 hasConceptScore W4379339735C121608353 @default.
• W4379339735 hasConceptScore W4379339735C126322002 @default.
• W4379339735 hasConceptScore W4379339735C141071460 @default.
• W4379339735 hasConceptScore W4379339735C142424586 @default.
• W4379339735 hasConceptScore W4379339735C143998085 @default.
• W4379339735 hasConceptScore W4379339735C2776364478 @default.
• W4379339735 hasConceptScore W4379339735C2776694085 @default.
• W4379339735 hasConceptScore W4379339735C2777701055 @default.
• W4379339735 hasConceptScore W4379339735C2780775027 @default.
• W4379339735 hasConceptScore W4379339735C2781413609 @default.
• W4379339735 hasConceptScore W4379339735C2911194787 @default.
• W4379339735 hasConceptScore W4379339735C3875195 @default.
• W4379339735 hasConceptScore W4379339735C71924100 @default.
• W4379339735 hasConceptScore W4379339735C72563966 @default.
• W4379339735 hasConceptScore W4379339735C87355193 @default.
• W4379339735 hasIssue "16_suppl" @default.
• W4379339735 hasLocation W43793397351 @default.
• W4379339735 hasOpenAccess W4379339735 @default.
• W4379339735 hasPrimaryLocation W43793397351 @default.
• W4379339735 hasRelatedWork W2096250489 @default.
• W4379339735 hasRelatedWork W2347651254 @default.
• W4379339735 hasRelatedWork W2370878625 @default.
• W4379339735 hasRelatedWork W2397183166 @default.
• W4379339735 hasRelatedWork W2408165734 @default.
• W4379339735 hasRelatedWork W2528057197 @default.
• W4379339735 hasRelatedWork W2751497063 @default.
• W4379339735 hasRelatedWork W3029718857 @default.
• W4379339735 hasRelatedWork W4212968510 @default.
• W4379339735 hasRelatedWork W4220700302 @default.
• W4379339735 hasVolume "41" @default.
• W4379339735 isParatext "false" @default.
• W4379339735 isRetracted "false" @default.
• W4379339735 workType "article" @default.